Patrick M Schlievert

List of Publications by Year
in descending order

298 papers	26,502 citations	6254 80 h-index	7745 150 g-index
302 all docs	302 docs citations	302 times ranked	13259 citing authors

#	Article	IF	Citations
1	TSST-1+ Staphylococcus aureus in Bullous Pemphigoid. Journal of Investigative Dermatology, 2022, 142, 1032-1039.e6.	0.7	9
2	Pathogen Stimulation of Interleukin-8 from Human Vaginal Epithelial Cells through CD40. Microbiology Spectrum, 2022, 10, e0010622.	3.0	3
3	Kawasaki syndrome: role of superantigens revisited. FEBS Journal, 2021, 288, 1771-1777.	4.7	10
4	Staphylococcal Enterotoxin C Subtypes Are Differentially Associated with Human Infections and Immunobiological Activities. MSphere, 2021, 6, .	2.9	4
5	Staphylococcal TSST-1 Association with Eczema Herpeticum in Humans. MSphere, 2021, 6, e0060821.	2.9	10
6	Effect of non-absorbent intravaginal menstrual/contraceptive products on Staphylococcus aureus and production of the superantigen TSST-1. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 31-38.	2.9	9
7	The lipid membrane of HIV-1 stabilizes the viral envelope glycoproteins and modulates their sensitivity to antibody neutralization. Journal of Biological Chemistry, 2020, 295, 348-362.	3.4	46
8	Human Keratinocyte Response to Superantigens. MSphere, 2020, 5, .	2.9	9
9	Decolonization of Human Anterior Nares of Staphylococcus aureus with Use of a Glycerol Monolaurate Nonaqueous Gel. MSphere, 2020, 5, .	2.9	1
10	Device-Associated Menstrual Toxic Shock Syndrome. Clinical Microbiology Reviews, 2020, 33, .	13.6	33
11	Five Percent Monolaurin Vaginal Gel for the Treatment of Bacterial Vaginosis: A Randomized Placebo-Controlled Trial. Journal of Lower Genital Tract Disease, 2020, 24, 277-283.	1.9	4
12	Menstrual TSS remains a dangerous threat. EClinicalMedicine, 2020, 21, 100316.	7.1	2
13	The SrrAB two-component system regulates Staphylococcus aureus pathogenicity through redox sensitive cysteines. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 10989-10999.	7.1	50
14	Case report of an unusual presentation of Staphylococcus aureus induced toxic shock syndrome/hyperimmunoglobulinemia E syndrome. Medicine (United States), 2020, 99, e19746.	1.0	2
15	Glycerol Monolaurate, an Analogue to a Factor Secreted by Lactobacillus , Is Virucidal against Enveloped Viruses, Including HIV-1. MBio, 2020, 11, .	4.1	30
16	Glycerol Monolaurate Contributes to the Antimicrobial and Anti-inflammatory Activity of Human Milk. Scientific Reports, 2019, 9, 14550.	3.3	35
17	Staphylococcal Superantigens Stimulate Epithelial Cells through CD40 To Produce Chemokines. MBio, 2019, 10, .	4.1	30
18	Toxins and Superantigens of Group A Streptococci. Microbiology Spectrum, 2019, 7, .	3.0	22

#	Article	IF	Citations
19	Toxins and Superantigens of Group A Streptococci. , 2019, , 55-66.		1
20	Staphylococcal Virulence Factors on the Skin of Atopic Dermatitis Patients. MSphere, 2019, 4, .	2.9	14
21	High Prevalence of Staphylococcus aureus Enterotoxin Gene Cluster Superantigens in Cystic Fibrosis Clinical Isolates. Genes, 2019, 10, 1036.	2.4	26
22	Glycerol Monolaurate (GML) and a Nonaqueous Five-Percent GML Gel Kill Bacillus and Clostridium Spores. MSphere, 2018, 3, .	2.9	14
23	Semen Exosomes Promote Transcriptional Silencing of HIV-1 by Disrupting NF-Î²B/Sp1/Tat Circuitry. Journal of Virology, 2018, 92, .	3.4	42
24	Septic transfusion case caused by a platelet pool with visible clotting due to contamination with Staphylococcus aureus. Transfusion, 2017, 57, 1299-1303.	1.6	23
25	Paneth cell disruption-induced necrotizing enterocolitis requires live bacteria and occurs independent of TLR4 signaling. DMM Disease Models and Mechanisms, 2017, 10, 727-736.	2.4	34
26	Staphylococcal Î²-Toxin Modulates Human Aortic Endothelial Cell and Platelet Function through Sphingomyelinase and Biofilm Ligase Activities. MBio, 2017, 8, .	4.1	30
27	Epidermal Growth Factor Receptor Signaling Enhances the Proinflammatory Effects of Staphylococcus aureus Gamma-Toxin on the Mucosa. Toxins, 2017, 9, 202.	3.4	7
28	The Staphylococcus aureus superantigen SElX is a bifunctional toxin that inhibits neutrophil function. PLoS Pathogens, 2017, 13, e1006461.	4.7	36
29	Novel Tissue Level Effects of the Staphylococcus aureus Enterotoxin Gene Cluster Are Essential for Infective Endocarditis. PLoS ONE, 2016, 11, e0154762.	2.5	44
30	Temporal and Racial Differences Associated with Atopic Dermatitis Staphylococcus aureus and Encoded Virulence Factors. MSphere, 2016, 1, .	2.9	25
31	Staphylococcus aureus Î²-Toxin Mutants Are Defective in Biofilm Ligase and Sphingomyelinase Activity, and Causation of Infective Endocarditis and Sepsis. Biochemistry, 2016, 55, 2510-2517.	2.5	26
32	The Spl Serine Proteases Modulate Staphylococcus aureus Protein Production and Virulence in a Rabbit Model of Pneumonia. MSphere, 2016, 1, .	2.9	53
33	Aortic Valve Damage for the Study of Left-Sided, Native Valve Infective Endocarditis in Rabbits. Methods in Molecular Biology, 2016, 1396, 73-80.	0.9	5
34	Rabbit Model for Superantigen-Mediated Lethal Pulmonary Disease. Methods in Molecular Biology, 2016, 1396, 81-93.	0.9	8
35	Local Epidermal Growth Factor Receptor Signaling Mediates the Systemic Pathogenic Effects of Staphylococcus aureus Toxic Shock Syndrome. PLoS ONE, 2016, 11, e0158969.	2.5	6
36	The Staphylococcus aureus Global Regulator MgrA Modulates Clumping and Virulence by Controlling Surface Protein Expression. PLoS Pathogens, 2016, 12, e1005604.	4.7	128

#	Article	IF	Citations
37	Identification, Purification, and Characterization of Staphylococcal Superantigens. Methods in Molecular Biology, 2016, 1396, 19-33.	0.9	3
38	Lipopolysaccharide-Induced Toxic Shock Syndrome in Rabbits. Methods in Molecular Biology, 2016, 1396, 67-71.	0.9	0
39	Non-Aqueous Glycerol Monolaurate Gel Exhibits Antibacterial and Anti-Biofilm Activity against Gram-Positive and Gram-Negative Pathogens. PLoS ONE, 2015, 10, e0120280.	2.5	22
40	Evaluation of the Enterococcus faecalis Biofilm-Associated Virulence Factors AhrC and Eep in Rat Foreign Body Osteomyelitis and In Vitro Biofilm-Associated Antimicrobial Resistance. PLoS ONE, 2015, 10, e0130187.	2.5	40
41	Glycerol Monolaurate Microbicide Protection against Repeat High-Dose SIV Vaginal Challenge. PLoS ONE, 2015, 10, e0129465.	2.5	27
42	Chronic Superantigen Exposure Induces Systemic Inflammation, Elevated Bloodstream Endotoxin, and Abnormal Glucose Tolerance in Rabbits: Possible Role in Diabetes. MBio, 2015, 6, e02554.	4.1	44
43	Novel Staphylococcus aureus Secreted Protein Alters Keratinocyte Proliferation and Elicits a Proinflammatory Response In Vitro and In Vivo. Biochemistry, 2015, 54, 4855-4862.	2.5	12
44	Reply to Dupieux et al. Journal of Infectious Diseases, 2015, 211, 847-848.	4.0	0
45	Does Staphylococcus aureus have a role in the development of Type 2 diabetes mellitus?. Future Microbiology, 2015, 10, 1549-1552.	2.0	8
46	Toxic shock syndrome toxin-1, not Î±-toxin, mediated Bundaberg fatalities. Microbiology (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 3	1.8	4
47	Determining the Presence of Superantigens in Coagulase Negative Staphylococci from Humans. PLoS ONE, 2015, 10, e0143341.	2.5	14
48	Novel Antimicrobial Peptides That Inhibit Gram Positive Bacterial Exotoxin Synthesis. PLoS ONE, 2014, 9, e95661.	2.5	13
49	Transcriptome Analysis of Enterococcus faecalis during Mammalian Infection Shows Cells Undergo Adaptation and Exist in a Stringent Response State. PLoS ONE, 2014, 9, e115839.	2.5	35
50	Are we close to a vaccination against Staphylococcus aureus?. Future Microbiology, 2014, 9, 717-720.	2.0	1
51	The dream of Staphylococcal vaccination. Journal of Experimental Medicine, 2014, 211, 2326-2326.	8.5	2
52	Staphylococcus aureus Î²-toxin Production is Common in Strains With the Î²-toxin Gene Inactivated by Bacteriophage. Journal of Infectious Diseases, 2014, 210, 784-792.	4.0	77
53	Vaccination Against Staphylococcus aureus Pneumonia. Journal of Infectious Diseases, 2014, 209, 1955-1962.	4.0	61
54	Molecular Analysis of Staphylococcal Superantigens. Methods in Molecular Biology, 2014, 1085, 169-185.	0.9	36

#	Article	IF	Citations
55	Superantigens of Staphylococcus aureus From Patients With Diabetic Foot Ulcers. Journal of Infectious Diseases, 2014, 210, 1920-1927.	4.0	30
56	Models matter: the search for an effective Staphylococcus aureus vaccine. Nature Reviews Microbiology, 2014, 12, 585-591.	28.6	179
57	Staphylococcal superantigens interact with multiple host receptors to cause serious diseases. Immunologic Research, 2014, 59, 177-181.	2.9	67
58	The Classical Lancefield Antigen of Group A Streptococcus Is a Virulence Determinant with Implications for Vaccine Design. Cell Host and Microbe, 2014, 15, 729-740.	11.0	121
59	Streptococcus agalactiae Toxic Shock-Like Syndrome. Medicine (United States), 2013, 92, 10-14.	1.0	16
60	The Staphylococcus aureus ArlRS Two-Component System Is a Novel Regulator of Agglutination and Pathogenesis. PLoS Pathogens, 2013, 9, e1003819.	4.7	78
61	Vaginal Toxic Shock Reaction Triggering Desquamative Inflammatory Vaginitis. Journal of Lower Genital Tract Disease, 2013, 17, 88-91.	1.9	17
62	Staphylococcal and Streptococcal Superantigen Exotoxins. Clinical Microbiology Reviews, 2013, 26, 422-447.	13.6	408
63	Superantigens Are Critical for Staphylococcus aureus Infective Endocarditis, Sepsis, and Acute Kidney Injury. MBio, 2013, 4, .	4.1	121
64	Genetic Variation among Panton-Valentine Leukocidin-Encoding Bacteriophages in Staphylococcus aureus Clonal Complex 30 Strains. Journal of Clinical Microbiology, 2013, 51, 914-919.	3.9	18
65	Menaquinone Analogs Inhibit Growth of Bacterial Pathogens. Antimicrobial Agents and Chemotherapy, 2013, 57, 5432-5437.	3.2	41
66	AhrC and Eep Are Biofilm Infection-Associated Virulence Factors in Enterococcus faecalis. Infection and Immunity, 2013, 81, 1696-1708.	2.2	65
67	Enterococcus faecalis Inhibits Superantigen Toxic Shock Syndrome Toxin-1-Induced Interleukin-8 from Human Vaginal Epithelial Cells through Tetramic Acids. PLoS ONE, 2013, 8, e61255.	2.5	11
68	Staphylococcal Superantigens Stimulate Immortalized Human Adipocytes to Produce Chemokines. PLoS ONE, 2013, 8, e77988.	2.5	32
69	Use of Recombinase-Based In Vivo Expression Technology To Characterize Enterococcus faecalis Gene Expression during Infection Identifies In Vivo -Expressed Antisense RNAs and Implicates the Protease Eep in Pathogenesis. Infection and Immunity, 2012, 80, 539-549.	2.2	54
70	Staphylococcus aureus Î±-toxin modulates skin host response to viral infection. Journal of Allergy and Clinical Immunology, 2012, 130, 683-691.e2.	2.9	67
71	Immunity to Staphylococcus aureus secreted proteins protects rabbits from serious illnesses. Vaccine, 2012, 30, 5099-5109.	3.8	66
72	A Disintegrin and Metalloproteinase 17 (ADAM17) and Epidermal Growth Factor Receptor (EGFR) Signaling Drive the Epithelial Response to Staphylococcus aureus Toxic Shock Syndrome Toxin-1 (TSST-1). Journal of Biological Chemistry, 2012, 287, 32578-32587.	3.4	25

#	Article	IF	Citations
73	Epithelial Proinflammatory Response and Curcumin-Mediated Protection from Staphylococcal Toxic Shock Syndrome Toxin-1. PLoS ONE, 2012, 7, e32813.	2.5	13
74	Glycerol Monolaurate Antibacterial Activity in Broth and Biofilm Cultures. PLoS ONE, 2012, 7, e40350.	2.5	139
75	Comparison of Staphylococcus aureus strains for ability to cause infective endocarditis and lethal sepsis in rabbits. Frontiers in Cellular and Infection Microbiology, 2012, 2, 18.	3.9	43
76	Alpha-Toxin Promotes Staphylococcus aureus Mucosal Biofilm Formation. Frontiers in Cellular and Infection Microbiology, 2012, 2, 64.	3.9	66
77	Ecto-5â€²-Nucleotidase: A Candidate Virulence Factor in Streptococcus sanguinis Experimental Endocarditis. PLoS ONE, 2012, 7, e38059.	2.5	54
78	Staphylococcus aureus Isolates Encode Variant Staphylococcal Enterotoxin B Proteins That Are Diverse in Superantigenicity and Lethality. PLoS ONE, 2012, 7, e41157.	2.5	17
79	Comparative proteomic profiling of patients with atopic dermatitis based on history of eczema herpeticum infection and Staphylococcus aureus colonization. Journal of Allergy and Clinical Immunology, 2011, 127, 186-193.e11.	2.9	116
80	Proinflammatory Exoprotein Characterization of Toxic Shock Syndrome Staphylococcus aureus. Biochemistry, 2011, 50, 7157-7167.	2.5	37
81	Beta-Hemolytic Streptococcal Erythroderma Syndrome: A Clinical and Pathogenic Analysis. American Journal of the Medical Sciences, 2011, 342, 343-344.	1.1	0
82	Staphylococcal Toxic Shock Syndrome 2000â€“2006: Epidemiology, Clinical Features, and Molecular Characteristics. PLoS ONE, 2011, 6, e22997.	2.5	117
83	Gramâ€positive bacterial superantigen outsideâ€in signaling causes toxic shock syndrome. FEBS Journal, 2011, 278, 4649-4667.	4.7	87
84	Brucella sp. vertebral osteomyelitis with intercurrent fatal Staphylococcus aureus toxigenic enteritis in a bottlenose dolphin (Tursiops truncatus). Journal of Veterinary Diagnostic Investigation, 2011, 23, 845-851.	1.1	22
85	Characterization of aStaphylococcus aureusSurface Virulence Factor That Promotes Resistance to Oxidative Killing and Infectious Endocarditis. Infection and Immunity, 2011, 79, 342-352.	2.2	30
86	A Novel Core Genome-Encoded Superantigen Contributes to Lethality of Community-Associated MRSA Necrotizing Pneumonia. PLoS Pathogens, 2011, 7, e1002271.	4.7	169
87	Staphylococcal Enterocolitis: Forgotten but Not Gone?. Digestive Diseases and Sciences, 2010, 55, 1200-1207.	2.3	27
88	A Single, Engineered Protein Therapeutic Agent Neutralizes Exotoxins from BothStaphylococcus aureusandStreptococcus pyogenes. Vaccine Journal, 2010, 17, 1781-1789.	3.1	18
89	Staphylococcus aureus Exotoxins Are Present In Vivo in Tampons. Vaccine Journal, 2010, 17, 722-727.	3.1	37
90	Staphylococcal Superantigens Cause Lethal Pulmonary Disease in Rabbits. Journal of Infectious Diseases, 2010, 202, 1690-1697.	4.0	64

#	Article	IF	Citations
91	Beta toxin catalyzes formation of nucleoprotein matrix in staphylococcal biofilms. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 14407-14412.	7.1	159
92	Glycerol Monolaurate Inhibits Candida and Gardnerella vaginalis In Vitro and In Vivo but Not Lactobacillus. Antimicrobial Agents and Chemotherapy, 2010, 54, 597-601.	3.2	59
93	Secreted virulence factor comparison between methicillin-resistant and methicillin-sensitive Staphylococcus aureus, and its relevance to atopic dermatitis. Journal of Allergy and Clinical Immunology, 2010, 125, 39-49.	2.9	163
94	Enterococcus faecalis Endocarditis Severity in Rabbits Is Reduced by IgG Fabs Interfering with Aggregation Substance. PLoS ONE, 2010, 5, e13194.	2.5	36
95	Glycerol Monolaurate and Dodecylglycerol Effects on Staphylococcus aureus and Toxic Shock Syndrome Toxin-1 In Vitro and In Vivo. PLoS ONE, 2009, 4, e7499.	2.5	37
96	Cytolysins Augment Superantigen Penetration of Stratified Mucosa. Journal of Immunology, 2009, 182, 2364-2373.	0.8	57
97	Staphylococcal Toxic Shock Syndrome Erythroderma Is Associated with Superantigenicity and Hypersensitivity. Clinical Infectious Diseases, 2009, 49, 1893-1896.	5.8	24
98	Multiple Functional Domains of Enterococcus faecalis Aggregation Substance Asc10 Contribute to Endocarditis Virulence. Infection and Immunity, 2009, 77, 539-548.	2.2	81
99	Cytolysins, Superantigens, and Pneumonia Due to Communityâ€Associated Methicillinâ€ResistantStaphylococcus aureus. Journal of Infectious Diseases, 2009, 200, 676-678.	4.0	34
100	Extreme Pyrexia and Rapid Death Due toStaphylococcus aureusInfection: Analysis of 2 Cases. Clinical Infectious Diseases, 2009, 48, 612-614.	5.8	19
101	Reduction inStaphylococcus aureusGrowth and Exotoxin Production and in Vaginal Interleukin 8 Levels Due to Glycerol Monolaurate in Tampons. Clinical Infectious Diseases, 2009, 49, 1711-1717.	5.8	26
102	Glycerol monolaurate prevents mucosal SIV transmission. Nature, 2009, 458, 1034-1038.	27.8	563
103	Severe Invasive Group A Streptococcal Disease with Rhabdomyolysis but without Evidence of Shock or Local Myositis. Scholarly Research Exchange, 2009, 2009, 1-3.	0.2	0
104	Porcine Vagina Ex Vivo as a Model for Studying Permeability and Pathogenesis in Mucosa. Journal of Pharmaceutical Sciences, 2008, 97, 9-21.	3.3	85
105	ELISA for human serum leucine-rich alpha-2-glycoprotein-1 employing cytochrome c as the capturing ligand. Journal of Immunological Methods, 2008, 336, 22-29.	1.4	53
106	Novel Toxic Shock Syndrome Toxin-1 Amino Acids Required for Biological Activity. Biochemistry, 2008, 47, 12995-13003.	2.5	33
107	Superantigen Profile ofStaphylococcus aureusIsolates from Patients with Steroidâ€Resistant Atopic Dermatitis. Clinical Infectious Diseases, 2008, 46, 1562-1567.	5.8	105
108	Neutralization of Multiple Staphylococcal Superantigens by a Singleâ€Chain Protein Consisting of Affinityâ€Matured, Variable Domain Repeats. Journal of Infectious Diseases, 2008, 198, 344-348.	4.0	20

#	Article	IF	Citations
109	Glycerol Monolaurate Does Not Alter Rhesus Macaque (Macaca mulatta) Vaginal Lactobacilli and Is Safe for Chronic Use. Antimicrobial Agents and Chemotherapy, 2008, 52, 4448-4454.	3.2	57
110	Staphylococcal and Streptococcal Toxic Shock and Kawasaki Syndromes. , 2008, , 129-134.		1
111	Chitosan Malate Inhibits Growth and Exotoxin Production of Toxic Shock Syndrome-Inducing Staphylococcus aureus Strains and Group A Streptococci. Antimicrobial Agents and Chemotherapy, 2007, 51, 3056-3062.	3.2	10
112	Sequence Analysis of the Staphylococcus aureus srrAB Loci Reveals that Truncation of srrA Affects Growth and Virulence Factor Expression. Journal of Bacteriology, 2007, 189, 7515-7519.	2.2	17
113	Toxic Shock-Like Syndrome Associated with Staphylococcal Enterocolitis in an HIV-Infected Man. Clinical Infectious Diseases, 2007, 44, e121-e123.	5.8	22
114	Structure and Biological Activities of Beta Toxin fromStaphylococcus aureus. Journal of Bacteriology, 2007, 189, 8719-8726.	2.2	128
115	Vaginal Staphylococcus aureus Superantigen Profile Shift from 1980 and 1981 to 2003, 2004, and 2005. Journal of Clinical Microbiology, 2007, 45, 2704-2707.	3.9	32
116	Crystal Structure of the Streptococcal Superantigen SpeI and Functional Role of a Novel Loop Domain in T Cell Activation by Group V Superantigens. Journal of Molecular Biology, 2007, 367, 925-934.	4.2	34
117	Repression ofStaphylococcus aureusSrrAB Using Inducible AntisensesrrAAlters Growth and Virulence Factor Transcript Levelsâ€. Biochemistry, 2007, 46, 314-321.	2.5	34
118	Î± and Î² Chains of Hemoglobin Inhibit Production of Staphylococcus aureus Exotoxins. Biochemistry, 2007, 46, 14349-14358.	2.5	55
119	The Two-Component System Bacillus Respiratory Response A and B (BrrAâ^'BrrB) Is a Virulence Factor Regulator in Bacillus anthracis. Biochemistry, 2007, 46, 7343-7352.	2.5	26
120	Neutralization of staphylococcal enterotoxin B by soluble, high-affinity receptor antagonists. Nature Medicine, 2007, 13, 725-729.	30.7	88
121	The staphylococcal respiratory response regulator SrrAB induces ica gene transcription and polysaccharide intercellular adhesin expression, protecting Staphylococcus aureus from neutrophil killing under anaerobic growth conditions. Molecular Microbiology, 2007, 65, 1276-1287.	2.5	94
122	The staphylococcal respiratory response regulator SrrAB induces ica gene transcription and polysaccharide intercellular adhesin expression, protecting Staphylococcus aureus from neutrophil killing under anaerobic growth conditions. Molecular Microbiology, 2007, 66, 278-278.	2.5	2
123	Molecular Analysis of Staphylococcal Superantigens. Methods in Molecular Biology, 2007, 391, 113-126.	0.9	62
124	Glycerol Monolaurate Inhibits the Effects of Gram-Positive Select Agents on Eukaryotic Cells. Biochemistry, 2006, 45, 2387-2397.	2.5	68
125	Staphylococcal Î±-toxin causes increased tracheal epithelial permeability. Pediatric Pulmonology, 2006, 41, 1146-1152.	2.0	19
126	An early favorable outcome of streptococcal toxic shock syndrome may require a combination of antimicrobial and intravenous gamma globulin therapy together with activated protein C. Scandinavian Journal of Infectious Diseases, 2006, 38, 960-963.	1.5	8

#	Article	IF	Citations
127	Staphylococcal toxic shock syndrome: still a problem. Medical Journal of Australia, 2005, 182, 651-652.	1.7	9
128	In vivo assessment of human vaginal oxygen and carbon dioxide levels during and post menses. Journal of Applied Physiology, 2005, 99, 1582-1591.	2.5	52
129	The Innate Immune System Is Activated by Stimulation of Vaginal Epithelial Cells with Staphylococcus aureus and Toxic Shock Syndrome Toxin 1. Infection and Immunity, 2005, 73, 2164-2174.	2.2	105
130	Purpura Fulminans Due toStaphylococcus aureus. Clinical Infectious Diseases, 2005, 40, 941-947.	5.8	196
131	Glycerol Monolaurate Inhibits Virulence Factor Production in Bacillus anthracis. Antimicrobial Agents and Chemotherapy, 2005, 49, 1302-1305.	3.2	41
132	Intravitreally Injected Human Immunoglobulin Attenuates the Effectsof Staphylococcus aureus Culture Supernatant in aRabbit Model of Toxin-Mediated Endophthalmitis. JAMA Ophthalmology, 2004, 122, 1499.	2.4	8
133	Characterization of Virulence Factor Regulation by SrrAB, a Two-Component System in Staphylococcus aureus. Journal of Bacteriology, 2004, 186, 2430-2438.	2.2	181
134	Reemergence of Staphylococcal Toxic Shock Syndrome in Minneapolis-St. Paul, Minnesota, during the 2000-2003 Surveillance Period. Journal of Clinical Microbiology, 2004, 42, 2875-2876.	3.9	75
135	An amino-terminal domain of Enterococcus faecalis aggregation substance is required for aggregation, bacterial internalization by epithelial cells and binding to lipoteichoic acid. Molecular Microbiology, 2004, 52, 1159-1171.	2.5	64
136	Virulence regulation inStaphylococcus aureus: the need for in vivo analysis of virulence factor regulation. FEMS Immunology and Medical Microbiology, 2004, 42, 147-154.	2.7	76
137	Temperature regulates bacterial protein production: possible role in rosacea. Journal of the American Academy of Dermatology, 2004, 50, 266-272.	1.2	84
138	A Possible Association of Recurrent Streptococcal Infections and Acute Onset of Obsessive-Compulsive Disorder. Journal of Neuropsychiatry and Clinical Neurosciences, 2004, 16, 252-260.	1.8	24
139	Expression, Purification, and Detection of Novel Streptococcal Superantigens. , 2003, 214, 033-043.		7
140	Pyrogenic, Lethal, and Emetic Properties of Superantigens in Rabbits and Primates. , 2003, 214, 245-253.		7
141	Structural, Energetic, and Functional Analysis of a Protein-Protein Interface at Distinct Stages of Affinity Maturation. Structure, 2003, 11, 1151-1161.	3.3	30
142	Penetration of toxic shock syndrome toxin-1 across porcine vaginal mucosa ex vivo: Permeability characteristics, toxin distribution, and tissue damage. American Journal of Obstetrics and Gynecology, 2003, 189, 1785-1791.	1.3	47
143	Augmentation of Staphylococcal Î±-Toxin Signaling by the Epidermal Platelet-Activating Factor Receptor. Journal of Investigative Dermatology, 2003, 120, 789-794.	0.7	16
144	Toxic shock syndrome in a horse with Staphylococcus aureus pneumonia. Journal of the American Veterinary Medical Association, 2003, 222, 620-623.	0.5	17

#	Article	IF	Citations
145	Effects of Total Body Irradiation and Cyclosporin A on the Lethality of Toxic Shock Syndrome Toxinâ€“1 in a Rabbit Model of Toxic Shock Syndrome. Journal of Infectious Diseases, 2003, 188, 1142-1145.	4.0	11
146	Functional Analysis of the TCR Binding Domain of Toxic Shock Syndrome Toxin-1 Predicts Further Diversity in MHC Class II/Superantigen/TCR Ternary Complexes. Journal of Immunology, 2003, 171, 1385-1392.	0.8	44
147	The Zinc-Dependent Major Histocompatibility Complex Class II Binding Site of Streptococcal Pyrogenic Exotoxin C Is Critical for Maximal Superantigen Function and Toxic Activity. Infection and Immunity, 2003, 71, 1548-1550.	2.2	20
148	Genome Diversification in Staphylococcus aureus : Molecular Evolution of a Highly Variable Chromosomal Region Encoding the Staphylococcal Exotoxin-Like Family of Proteins. Infection and Immunity, 2003, 71, 2827-2838.	2.2	114
149	Characterization of Staphylococcus aureus Enterotoxin L. Infection and Immunity, 2003, 71, 2916-2919.	2.2	102
150	Hospital Transmission of Community-Acquired Methicillin-Resistant Staphylococcus aureus among Postpartum Women. Clinical Infectious Diseases, 2003, 37, 1313-1319.	5.8	380
151	Comparative Molecular Analysis of Community- or Hospital-Acquired Methicillin-Resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2003, 47, 196-203.	3.2	301
152	A Superantigen Hypothesis for the Pathogenesis of Chronic Hyperplastic Sinusitis with Massive Nasal Polyposis. American Journal of Rhinology & Allergy, 2003, 17, 321-326.	2.2	119
153	Quorum sensing in Staphylococcus infections. Journal of Clinical Investigation, 2003, 112, 1620-1625.	8.2	249
154	Quorum sensing in Staphylococcus infections. Journal of Clinical Investigation, 2003, 112, 1620-1625.	8.2	189
155	A superantigen hypothesis for the pathogenesis of chronic hyperplastic sinusitis with massive nasal polyposis. American Journal of Rhinology & Allergy, 2003, 17, 321-6.	2.2	27
156	Repression of the Staphylococcus aureus Accessory Gene Regulator in Serum and In Vivo. Journal of Bacteriology, 2002, 184, 1095-1101.	2.2	108
157	Genome sequence of a serotype M3 strain of group A Streptococcus: Phage-encoded toxins, the high-virulence phenotype, and clone emergence. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 10078-10083.	7.1	452
158	Characterization and Expression Analysis of Staphylococcus aureus Pathogenicity Island 3. Journal of Biological Chemistry, 2002, 277, 13138-13147.	3.4	123
159	Characterization of Two Novel Pyrogenic Toxin Superantigens Made by an Acute Rheumatic Fever Clone of Streptococcus pyogenes Associated with Multiple Disease Outbreaks. Infection and Immunity, 2002, 70, 7095-7104.	2.2	66
160	In Vivo Induction of Virulence and Antibiotic Resistance Transfer in Enterococcus faecalis Mediated by the Sex Pheromone-Sensing System of pCF10. Infection and Immunity, 2002, 70, 716-723.	2.2	81
161	Recurrent Nonmenstrual Toxic Shock. Clinical Infectious Diseases, 2002, 34, 289-289.	5.8	3
162	Formation of Vegetations during Infective Endocarditis Excludes Binding of Bacterialâ€Specific Host Antibodies toEnterococcus faecalis. Journal of Infectious Diseases, 2002, 185, 994-997.	4.0	43

#	Article	IF	Citations
163	Characterization of a Novel Staphylococcal Enterotoxin-like Superantigen, a Member of the Group V Subfamily of Pyrogenic Toxins. Biochemistry, 2002, 41, 14033-14040.	2.5	104
164	Prevalence of superantigen-secreting bacteria in patients with Kawasaki disease. Journal of Pediatrics, 2002, 140, 742-746.	1.8	121
165	Structures of Two Streptococcal Superantigens Bound to TCR Î² Chains Reveal Diversity in the Architecture of T Cell Signaling Complexes. Structure, 2002, 10, 687-699.	3.3	116
166	Toxic Shock Syndrome and Bacterial Superantigens: An Update. Annual Review of Microbiology, 2001, 55, 77-104.	7.3	683
167	Use of intravenous immunoglobulin in the treatment of staphylococcal and streptococcal toxic shock syndromes and related illnessesâ˜†â˜†â˜†. Journal of Allergy and Clinical Immunology, 2001, 108, S107-S110.	2.9	83
168	Prolonged course of toxic shock syndrome associated with methicillin-resistant Staphylococcus aureus enterotoxins G and I. International Journal of Infectious Diseases, 2001, 5, 163-166.	3.3	12
169	Crystal Structure of a Superantigen Bound to the High-Affinity, Zinc-Dependent Site on MHC Class II. Immunity, 2001, 14, 93-104.	14.3	134
170	Toxic shock syndrome after laminaria insertion1. Obstetrics and Gynecology, 2001, 98, 959-961.	2.4	14
171	Pathogenicity and resistance islands of staphylococci. Microbes and Infection, 2001, 3, 585-594.	1.9	131
172	Biochemical and Biological Properties of Staphylococcal Enterotoxin K. Infection and Immunity, 2001, 69, 360-366.	2.2	192
173	Comparative Analysis of Lipopolysaccharide-Induced Tumor Necrosis Factor Alpha Activity in Serum and Lethality in Mice and Rabbits Pretreated with the Staphylococcal Superantigen Toxic Shock Syndrome Toxin 1. Infection and Immunity, 2001, 69, 7169-7172.	2.2	61
174	Antibodies to a Surface-Exposed, N-terminal Domain of Aggregation Substance Are Not Protective in the Rabbit Model of Enterococcus faecalis Infective Endocarditis. Infection and Immunity, 2001, 69, 3305-3314.	2.2	35
175	Functional Characterization of Streptococcal Pyrogenic Exotoxin J, a Novel Superantigen. Infection and Immunity, 2001, 69, 1381-1388.	2.2	45
176	Role of T Cells and Gamma Interferon during Induction of Hypersensitivity to Lipopolysaccharide by Toxic Shock Syndrome Toxin 1 in Mice. Infection and Immunity, 2001, 69, 1256-1264.	2.2	51
177	Molecular Characterization of a NovelStaphylococcus aureus Serine Protease Operon. Infection and Immunity, 2001, 69, 1521-1527.	2.2	129
178	Identification of a Novel Two-Component Regulatory System That Acts in Global Regulation of Virulence Factors ofStaphylococcus aureus. Journal of Bacteriology, 2001, 183, 1113-1123.	2.2	281
179	Purification of Streptococcal Pyrogenic Exotoxin A. , 2000, 36, 59-66.		1
180	Will therapeutic peptides be kryptonite for superantigens?. Nature Medicine, 2000, 6, 378-379.	30.7	9

#	Article	IF	Citations
181	Evidence for the involvement of bacterial superantigens in psoriasis, atopic dermatitis, and Kawasaki syndrome. FEMS Microbiology Letters, 2000, 192, 1-7.	1.8	84
182	Structure of streptococcal pyrogenic exotoxin A reveals a novel metal cluster. Protein Science, 2000, 9, 1847-1851.	7.6	29
183	Pathogenic mechanisms of enterococcal endocarditis. Current Infectious Disease Reports, 2000, 2, 315-321.	3.0	29
184	Structural Evidence for the Evolution of Pyrogenic Toxin Superantigens. Journal of Molecular Evolution, 2000, 51, 520-531.	1.8	46
185	Exotoxins ofStaphylococcus aureus. Clinical Microbiology Reviews, 2000, 13, 16-34.	13.6	1,232
186	Mutational Analysis of the Superantigen Staphylococcal Exfoliative Toxin A (ETA). Journal of Immunology, 2000, 164, 2207-2213.	0.8	27
187	Development of Streptococcal Pyrogenic Exotoxin C Vaccine Toxoids That Are Protective in the Rabbit Model of Toxic Shock Syndrome. Journal of Immunology, 2000, 165, 2306-2312.	0.8	66
188	Toxoids of Streptococcal Pyrogenic Exotoxin A Are Protective in Rabbit Models of Streptococcal Toxic Shock Syndrome. Infection and Immunity, 2000, 68, 5011-5017.	2.2	71
189	Staphylococcal Exfoliative Toxins Cleave Î±- and Î²-Melanocyte-Stimulating Hormones. Infection and Immunity, 2000, 68, 2366-2368.	2.2	22
190	Pyrogenic Toxin Superantigen Site Specificity in Toxic Shock Syndrome and Food Poisoning in Animals. Infection and Immunity, 2000, 68, 3630-3634.	2.2	95
191	Application of staphylococcal enterotoxin B on normal and atopic skin induces up-regulation of T cells by a superantigen-mediated mechanism. Journal of Allergy and Clinical Immunology, 2000, 105, 820-826.	2.9	136
192	Evidence for the involvement of bacterial superantigens in psoriasis, atopic dermatitis, and Kawasaki syndrome. FEMS Microbiology Letters, 2000, 192, 1-7.	1.8	5
193	Oxygen and Carbon Dioxide Regulation of Toxic Shock Syndrome Toxin 1 Production by Staphylococcus aureus MN8. Journal of Clinical Microbiology, 2000, 38, 1797-1803.	3.9	75
194	Kawasaki Syndrome-Like Illness Associated with Infection Caused by Enterotoxin B-Secreting Staphylococcus aureus. Clinical Infectious Diseases, 1999, 29, 586-589.	5.8	36
195	Staphylococcal Toxins Augment Specific IgE Responses by Atopic Patients Exposed to Allergen. Journal of Investigative Dermatology, 1999, 112, 171-176.	0.7	100
196	Role of the T Cell Receptor Î± Chain in Stabilizing TCR-Superantigen-MHC Class II Complexes. Immunity, 1999, 10, 473-483.	14.3	81
197	The Crystal Structure of Exfoliative Toxin B:Â A Superantigen with Enzymatic Activityâ€,â€¡. Biochemistry, 1999, 38, 10239-10246.	2.5	65
198	Staphylococcus aureusIsolates from Patients with Kawasaki Disease Express High Levels of Protein A. Infection and Immunity, 1999, 67, 4737-4743.	2.2	15

#	Article	IF	Citations
199	Epidermal HLA-DR and the enhancement of cutaneous reactivity to superantigenic toxins in psoriasis. Journal of Clinical Investigation, 1999, 104, 1181-1189.	8.2	58
200	Use of electroporation in genetic analysis of enterococcal virulence. Cytotechnology, 1998, 20, 79-84.	0.7	1
201	The immunopathogenesis and management of Kawasaki syndrome. Arthritis and Rheumatism, 1998, 41, 1538-1547.	6.7	60
202	Three-Dimensional Structure of the Complex between a T Cell Receptor Î² Chain and the Superantigen Staphylococcal Enterotoxin B. Immunity, 1998, 9, 807-816.	14.3	188
203	Structures of Five Mutants of Toxic Shock Syndrome Toxin-1 with Reduced Biological Activityâ€,â€¡. Biochemistry, 1998, 37, 7194-7202.	2.5	30
204	A Mutational Analysis of the Binding of Staphylococcal Enterotoxins B and C3 to the T Cell Receptor Î² Chain and Major Histocompatibility Complex Class II. Journal of Experimental Medicine, 1998, 187, 823-833.	8.5	145
205	My Experiences with Toxic Shock Syndrome Research. Infectious Diseases in Clinical Practice, 1998, 7, 459-462.	0.3	0
206	Scalded skin syndrome. Reviews in Medical Microbiology, 1998, 9, 9-16.	0.9	5
207	Molecular epidemiology of staphylococcal scalded skin syndrome in premature infants. Pediatric Infectious Disease Journal, 1998, 17, 329-334.	2.0	44
208	Aggregation and Binding Substances Enhance Pathogenicity in Rabbit Models ofEnterococcus faecalisEndocarditis. Infection and Immunity, 1998, 66, 218-223.	2.2	160
209	Reply: Toxin-Producing Staphylococcus aureus and Kawasaki Disease. Pediatric Research, 1998, 43, 291-293.	2.3	0
210	The etiology and pathogenesis of Kawasaki disease â€“ how close are we to an answer?. Current Opinion in Infectious Diseases, 1997, 10, 226-232.	3.1	13
211	The Structure of the Superantigen Exfoliative Toxin A Suggests a Novel Regulation as a Serine Proteaseâ€,â€¡. Biochemistry, 1997, 36, 1559-1566.	2.5	136
212	Purification ofStaphylococcus aureusÎ²-Toxin: Comparison of Three Isoelectric Focusing Methods. Protein Expression and Purification, 1997, 9, 76-82.	1.3	7
213	Refined structures of three crystal forms of toxic shock syndrome toxinâ€1 and of a tetramutant with reduced activity. Protein Science, 1997, 6, 1220-1227.	7.6	26
214	Loxosceles arizonica Bite Associated With Shock. Annals of Emergency Medicine, 1997, 30, 701-703.	0.6	35
215	Novel Superantigens from Streptococcal Toxic Shock Syndrome Streptococcus pyogenes Isolates. Advances in Experimental Medicine and Biology, 1997, 418, 525-529.	1.6	5
216	Association of Toxic Shock Syndrome Toxin-Secreting and Exfoliative Toxin-Secreting Staphylococcus aureus with Kawasaki Syndrome Complicated by Coronary Artery Disease. Pediatric Research, 1997, 42, 268-272.	2.3	36

#	Article	IF	Citations
217	Tampons and toxic shock syndrome. Medical Journal of Australia, 1996, 164, 635-636.	1.7	2
218	Severe invasive group A streptococcal disease: Clinical description and mechanisms of pathogenesis. Translational Research, 1996, 127, 13-22.	2.3	100
219	Crystal structure of a T-cell receptor Î²-chain complexed with a superantigen. Nature, 1996, 384, 188-192.	27.8	295
220	The Staphylococcal and Streptococcal Pyrogenic Toxin Family. Advances in Experimental Medicine and Biology, 1996, 391, 131-154.	1.6	26
221	Structure of Toxic Shock Syndrome Toxin-1. Molecular Biology Intelligence Unit, 1996, , 217-229.	0.2	1
222	Invasive group A streptococcal infections in children with varicella in Southern California. Pediatric Infectious Disease Journal, 1996, 15, 146-150.	2.0	90
223	The role of superantigens in human diseases. Current Opinion in Infectious Diseases, 1995, 8, 170-174.	3.1	29
224	Invasive group B streptococcal disease in children beyond early infancy. Pediatric Infectious Disease Journal, 1995, 14, 278-280.	2.0	56
225	Molecular structure of staphylococcus and streptococcus superantigens. Journal of Clinical Immunology, 1995, 15, S4-S10.	3.8	50
226	The potential role of bacterial superantigens in the pathogenesis of Kawasaki syndrome. Journal of Clinical Immunology, 1995, 15, S11-S17.	3.8	37
227	Superantigens in Kawasaki Syndrome. Clinical Immunology and Immunopathology, 1995, 77, 119-126.	2.0	29
228	Bacterial superantigens induce T cell expression of the skin-selective homing receptor, the cutaneous lymphocyte-associated antigen, via stimulation of interleukin 12 production.. Journal of Experimental Medicine, 1995, 181, 747-753.	8.5	300
229	Successful Management of a Serious Group A Streptococcal Infection During the Third Trimester of Pregnancy. Clinical Infectious Diseases, 1995, 21, 1058-1059.	5.8	7
230	Selective Depletion Of VÂ-Bearing T Cells In Patients With Severe Invasive Group A Streptococcal Infections And Streptococcal Toxic Shock Syndrome. Journal of Infectious Diseases, 1995, 171, 74-84.	4.0	115
231	Superantigen binding to a T cell receptor beta chain of known three-dimensional structure.. Journal of Experimental Medicine, 1995, 182, 1833-1845.	8.5	124
232	Mechanisms of Immunoglobulin Action: Observations on Kawasaki Syndrome and RSV Prophylaxis. Immunological Reviews, 1994, 139, 109-123.	6.0	29
233	Dual infections with Staphylococcus aureus and Streptococcus pyogenes causing toxic shock syndrome possible synergistic effects of toxic shock syndrome toxin 1 and streptococcal pyrogenic exotoxin C. Diagnostic Microbiology and Infectious Disease, 1994, 19, 245-247.	1.8	13
234	Glycerol monolaurate inhibits the production of beta-lactamase, toxic shock toxin-1, and other staphylococcal exoproteins by interfering with signal transduction. Journal of Bacteriology, 1994, 176, 4204-4209.	2.2	135

#	Article	IF	Citations
235	Streptococcal toxic shock syndrome, including necrotizing fasciitis and myositis. Current Opinion in Infectious Diseases, 1994, 7, 423-426.	3.1	20
236	Growth and analysis of crystal forms of toxic shock syndrome toxin 1. Proteins: Structure, Function and Bioinformatics, 1993, 17, 329-334.	2.6	8
237	Analysis of the TCR VÎ² Specificities of Bacterial Superantigens Using PCR. ImmunoMethods, 1993, 2, 33-40.	0.8	21
238	Structure of toxic shock syndrome toxin 1. Biochemistry, 1993, 32, 13761-13766.	2.5	155
239	Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet, The, 1993, 342, 1385-1388.	13.7	378
240	Role of Superantigens in Human Disease. Journal of Infectious Diseases, 1993, 167, 997-1002.	4.0	345
241	Severe Invasive Group A Streptococcal Infections In Ontario, Canada: 1987-1991. Clinical Infectious Diseases, 1993, 16, 792-800.	5.8	225
242	Geographic and Temporal Distribution and Molecular Characterization of Two Highly Pathogenic Clones ofStreptococcus pyogenesExpressing Allelic Variants of Pyrogenic Exotoxin A (Scarlet) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	5.8	142
243	Group B Streptococcal Toxic Shock-Like Syndrome: Report of a Case and Purification of an Associated Pyrogenic Toxin. Clinical Infectious Diseases, 1993, 17, 26-31.	5.8	61
244	Group A Streptococcal Bacteremia in a Mid-South ChildrenÊ¼s Hospital. Southern Medical Journal, 1993, 86, 615-618.	0.7	20
245	A Recalcitrant, Erythematous, Desquamating Disorder Associatedwith Toxin-Producing Staphylococci in Patients with AIDS. Journal of Infectious Diseases, 1992, 165, 638-643.	4.0	75
246	Effect of glycerol monolaurate on bacterial growth and toxin production. Antimicrobial Agents and Chemotherapy, 1992, 36, 626-631.	3.2	107
247	Ribavirin mitigates wart growth in rabbits at early stages of infection with cottontail rabbit papillomavirus. Antiviral Research, 1992, 17, 99-113.	4.1	19
248	Clonal basis for resurgence of serious Streptococcus pyogenes disease in the 1980s. Lancet, The, 1992, 339, 518-521.	13.7	321
249	Rat liver protein linking chemical and immunological detoxification systems. Nature, 1992, 360, 269-270.	27.8	73
250	Characterization and clonal distribution of four alleles of the speA gene encoding pyrogenic exotoxin A (scarlet fever toxin) in Streptococcus pyogenes.. Journal of Experimental Medicine, 1991, 174, 1271-1274.	8.5	112
251	TOXIC SHOCK-LIKE SYNDROME, A COMPLICATION OF STREP THROAT. Pediatric Infectious Disease Journal, 1991, 10, 790.	2.0	13
252	Association of exotoxin-producing Group A streptococci and severe disease in children. Pediatric Infectious Disease Journal, 1991, 10, 351-354.	2.0	75

#	Article	IF	Citations
253	STREPTOCOCCAL TOXIC SHOCK-LIKE SYNDROME AS A COMPLICATION OF VARICELLA. Pediatric Infectious Disease Journal, 1991, 10, 77-78.	2.0	43
254	Transmission of ?Toxic Strep? syndrome from an infected child to a firefighter during CPR. Annals of Emergency Medicine, 1991, 20, 90-92.	0.6	55
255	Streptococcus pyogenes causing toxic-shock-like syndrome and other invasive diseases: clonal diversity and pyrogenic exotoxin expression.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 2668-2672.	7.1	439
256	A single clone of Staphylococcus aureus causes the majority of cases of toxic shock syndrome.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 225-229.	7.1	184
257	Nucleotide sequence of the streptococcal pyrogenic exotoxin type B gene and relationship between the toxin and the streptococcal proteinase precursor. Journal of Bacteriology, 1990, 172, 4536-4542.	2.2	172
258	Staphylococcal and Streptococcal Pyrogenic Toxins Involved in Toxic Shock Syndrome and Related Illnesses. Critical Reviews in Microbiology, 1990, 17, 251-272.	6.1	481
259	Toxic Shock Syndrome Toxin 1 Is Encoded by a Variable Genetic Element. Clinical Infectious Diseases, 1989, 11, S83-S89.	5.8	35
260	Severe Group A Streptococcal Infections Associated with a Toxic Shock-like Syndrome and Scarlet Fever Toxin A. New England Journal of Medicine, 1989, 321, 1-7.	27.0	1,250
261	Group a streptococcal peritonitis in a patient undergoing continuous ambulatory peritoneal dialysis. American Journal of Medicine, 1989, 86, 249-250.	1.5	17
262	Treatment of toxic shock syndrome with endotoxin-neutralizing antibody. Journal of Surgical Research, 1989, 46, 527-531.	1.6	20
263	Group a streptococcal peritonitis associated with continuous ambulatory peritoneal dialysis. American Journal of Medicine, 1989, 87, 487.	1.5	0
264	Analysis of Toxic Shock Syndrome Isolates Producing Staphylococcal Enterotoxins B and Cl with Use of Southern Hybridization and Immunologic Assays. Clinical Infectious Diseases, 1989, 11, S75-S82.	5.8	50
265	Role of Toxic Shock Syndrome Toxin 1 in Toxic Shock Syndrome: Overview. Clinical Infectious Diseases, 1989, 11, S107-S109.	5.8	9
266	Cloning and characterization of the gene, speC, for pyrogenic exotoxin type C from Streptococcus pyogenes. Molecular Genetics and Genomics, 1988, 212, 66-70.	2.4	39
267	[47] Immunochemical assays for toxic shock syndrome toxin-1. Methods in Enzymology, 1988, 165, 339-344.	1.0	37
268	[6] Preparation of toxic shock syndrome toxin-1. Methods in Enzymology, 1988, 165, 37-43.	1.0	86
269	Cloning, characterization, and sequencing of an accessory gene regulator (agr) in Staphylococcus aureus. Journal of Bacteriology, 1988, 170, 4365-4372.	2.2	535
270	Clinical and Bacteriologic Observations of a Toxic Shockâ€“like Syndrome Due toStreptococcus pyogenes. New England Journal of Medicine, 1987, 317, 146-149.	27.0	605

#	Article	IF	Citations
271	Nucleotide sequence of the staphylococcal enterotoxin C1 gene and relatedness to other pyrogenic toxins. Molecular Genetics and Genomics, 1987, 209, 15-20.	2.4	137
272	Toxic shock syndrome. A newly recognized complication of influenza and influenzalike illness. JAMA - Journal of the American Medical Association, 1987, 257, 1053-1058.	7.4	155
273	Resolution of highly purified toxic-shock syndrome toxin 1 into two distinct proteins by isoelectric focusing. Biochemistry, 1986, 25, 54-59.	2.5	43
274	Regulation of exoprotein gene expression in Staphylococcus aureus by agr. Molecular Genetics and Genomics, 1986, 202, 58-61.	2.4	564
275	Streptococcal pyrogenic exotoxin type A (scarlet fever toxin) is related to Staphylococcus aureus enterotoxin B. Molecular Genetics and Genomics, 1986, 203, 354-356.	2.4	90
276	Suppression of Immunoglobulin-Secreting Cells from Human Peripheral Blood by Toxic-Shockâ€"Syndrome Toxin-1. Journal of Infectious Diseases, 1986, 153, 772-779.	4.0	58
277	Toxic-Shock-Syndrome Toxin 1-Induced Proliferation of Lymphocytes: Comparison of the Mitogenic Response of Human, Murine, and Rabbit Lymphocytes. Journal of Infectious Diseases, 1985, 151, 65-72.	4.0	109
278	The Biochemical and Immunological Properties of Toxic-Shock Syndrome Toxin-1 (Tsst-1) and Association with TSS. Toxin Reviews, 1985, 4, 1-39.	1.5	21
279	Group A streptococcal phage T12 carries the structural gene for pyrogenic exotoxin type A. Molecular Genetics and Genomics, 1984, 194, 52-56.	2.4	97
280	The toxic shock syndrome exotoxin structural gene is not detectably transmitted by a prophage. Nature, 1983, 305, 709-712.	27.8	1,295
281	A physical map of the group A streptococcal pyrogenic exotoxin bacteriophage T12 genome. Molecular Genetics and Genomics, 1983, 189, 251-255.	2.4	26
282	Production of Staphylococcal Pyrogenic Exotoxin Type C: Influence of Physical and Chemical Factors. Journal of Infectious Diseases, 1983, 147, 236-242.	4.0	209
283	Toxin and Enzyme Characterization of Staphylococcus aureus Isolates from Patients With and Without Toxic Shock Syndrome. Annals of Internal Medicine, 1982, 96, 937.	3.9	91
284	Staphylococcal Pyrogenic Exotoxin Type C: Further Characterization. Annals of Internal Medicine, 1982, 96, 982.	3.9	33
285	Identification and Characterization of an Exotoxin from Staphylococcus aureus Associated with Toxic-Shock Syndrome. Journal of Infectious Diseases, 1981, 143, 509-516.	4.0	735
286	Permeability of the middle ear to staphylococcal pyrogenic exotoxin in otitis media. International Journal of Pediatric Otorhinolaryngology, 1980, 1, 301-308.	1.0	49
287	Purification and characterization of staphylococcal pyrogenic exotoxin type B. Biochemistry, 1980, 19, 6204-6208.	2.5	37
288	Bacterial growth inhibition by amniotic fluid. American Journal of Obstetrics and Gynecology, 1977, 127, 603-608.	1.3	24

#	Article	IF	Citations
289	Bacterial growth inhibition by amniotic fluid. American Journal of Obstetrics and Gynecology, 1976, 125, 906-910.	1.3	67
290	Bacterial growth inhibition by amniotic fluid. American Journal of Obstetrics and Gynecology, 1976, 125, 899-905.	1.3	58
291	Bacterial growth inhibition by amniotic fluid. American Journal of Obstetrics and Gynecology, 1975, 122, 809-813.	1.3	56
292	Bacterial growth inhibition by amniotic fluid. American Journal of Obstetrics and Gynecology, 1975, 122, 814-819.	1.3	12
293	The spectrum of antibacterial activity of human amniotic fluid determined by scanning electron microscopy. American Journal of Obstetrics and Gynecology, 1974, 119, 895-903.	1.3	9
294	Staphylococcal and streptococcal toxic shock and Kawasaki syndromes. , 0, , 127-132.		0
295	Toxins and Superantigens of Group A Streptococci. , 0, , 47-58.		7
296	Staphylococcal and Streptococcal Superantigens: an Update. , 0, , 21-36.		5
297	Staphylococcal and Streptococcal Superantigens. , 0, , 293-308.		0
298	Molecular Analysis of Staphylococcal Superantigens. , 0, , 113-126.		0